ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

stada pharmaceuticals australia pty ltd - carbidopa monohydrate, quantity: 40.5 mg (equivalent: carbidopa, qty 37.5 mg); entacapone, quantity: 200 mg; levodopa, quantity: 150 mg - tablet, film coated - excipient ingredients: trehalose dihydrate; hyprolose; magnesium stearate; microcrystalline cellulose; sodium sulfate; carmellose sodium; powdered cellulose; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

stada pharmaceuticals australia pty ltd - carbidopa monohydrate, quantity: 33.75 mg (equivalent: carbidopa, qty 31.25 mg); entacapone, quantity: 200 mg; levodopa, quantity: 125 mg - tablet, film coated - excipient ingredients: magnesium stearate; powdered cellulose; sodium sulfate; hyprolose; microcrystalline cellulose; trehalose dihydrate; carmellose sodium; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

stada pharmaceuticals australia pty ltd - levodopa, quantity: 75 mg; carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: trehalose dihydrate; microcrystalline cellulose; carmellose sodium; hyprolose; sodium sulfate; magnesium stearate; powdered cellulose; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

इसराइल - अंग्रेज़ी - Ministry of Health

raz pharmaceutics ltd, israel - dopamine hydrochloride - concentrate for solution for infusion - dopamine hydrochloride 40 mg / 1 ml - dopamine - dopamine hydrochloride s.a.l.f. is used for the treatment of states of shock of different nature:- post myocardial infarction cardiogenic shock, a shock caused by a heart attack,- surgical shock, caused by a surgical operation,- hypovolemic or haemorrhagic shock, caused by a decrease in blood volume due to a hemorrhage,a shock is characterized by a sharp decrease in blood pressure in response to a reduced blood flow in the organism.

यूरोपीय संघ - अंग्रेज़ी - EMA (European Medicines Agency)

orion corporation - levodopa, carbidopa, entacapone - parkinson disease - nervous system - levodopa/carbidopa/entacapone orion is indicated for the treatment of adult patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (ddc)-inhibitor treatment.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j), entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t) - carbidopa anhydrous 12.5 mg - carbidopa, levodopa and entacapone tablets, a combination drug consisting of levodopa, carbidopa (dopa decarboxylase inhibitor), and entacapone (catechol-o-methyltransferase-comt inhibitor) is indicated for the treatment of parkinson’s disease. carbidopa, levodopa and entacapone tablets can be used: - to substitute (with equivalent strengths of each of the three components) carbidopa/levodopa and entacapone previously administered as individual products. - to replace carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose “wearing-off” and when they have been taking a total daily dose of levodopa of 600 mg or less and have not been experiencing dyskinesias. carbidopa, levodopa and entacapone tablets are contraindicated in patients: - taking nonselective monoamine oxidase (mao) inhibitors (e.g., phenelzine and tranylcypromine). these nonselective mao inhibitors must be discontinued at least two weeks prior to initiating therapy with carbidopa, levodo

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

wockhardt usa llc. - levodopa (unii: 46627o600j) (levodopa - unii:46627o600j), entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t), carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh) - levodopa 50 mg - carbidopa, levodopa and entacapone tablets, a combination drug consisting of levodopa, carbidopa (dopa decarboxylase inhibitor), and entacapone (catechol-o-methyltransferase-comt inhibitor) is indicated for the treatment of parkinson's disease. carbidopa, levodopa and entacapone tablets can be used: - to substitute (with equivalent strengths of each of the three components) carbidopa/levodopa and entacapone previously administered as individual products. - to replace carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose "wearing-off" and when they have been taking a total daily dose of levodopa of 600 mg or less and have not been experiencing dyskinesias. carbidopa, levodopa and entacapone tablets are contraindicated in patients: - taking nonselective monoamine oxidase (mao) inhibitors (e.g., phenelzine and tranylcypromine). these nonselective mao inhibitors must be discontinued at least two weeks prior to in

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j), entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t) - carbidopa anhydrous 12.5 mg - carbidopa, levodopa and entacapone tablets, a combination drug consisting of levodopa, carbidopa (dopa decarboxylase inhibitor), and entacapone (catechol-o-methyltransferase-comt inhibitor) is indicated for the treatment of parkinson’s disease. carbidopa, levodopa and entacapone tablets can be used: carbidopa, levodopa and entacapone tablets are contraindicated in patients: there are no adequate and well-controlled studies in pregnant women. it has been reported from individual cases that levodopa crosses the human placental barrier, enters the fetus, and is metabolized. in animals, administration of carbidopa-levodopa or entacapone during pregnancy was associated with developmental toxicity, including increased incidences of fetal malformations. carbidopa, levodopa and entacapone tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in nonclinical studies in which carbidopa-levodopa was administered to pregnant animals, increased incidences of viscer

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

sandoz inc - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j), entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t) - carbidopa anhydrous 50 mg - carbidopa, levodopa and entacapone tablets, a combination drug consisting of levodopa, carbidopa (dopa decarboxylase inhibitor), and entacapone (catechol-o-methyltransferase-comt inhibitor) are indicated for the treatment of parkinson's disease. carbidopa, levodopa and entacapone tablets can be used: carbidopa, levodopa and entacapone tablets are contraindicated in patients: pregnancy category c there are no adequate and well-controlled studies in pregnant women. it has been reported from individual cases that levodopa crosses the human placental barrier, enters the fetus, and is metabolized. in animals, administration of carbidopa-levodopa or entacapone during pregnancy was associated with developmental toxicity, including increased incidences of fetal malformations. carbidopa, levodopa and entacapone tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in nonclinical studies in which carbidopa-levodopa was administered to pregnant animals, increase

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

golden state medical supply - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa anhydrous 10 mg - carbidopa and levodopa tablets are indicated in the treatment of parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. carbidopa allows patients treated for parkinson's disease to use much lower doses of levodopa. some patients who responded poorly to levodopa have improved on carbidopa and levodopa tablets. this is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. carbidopa may also reduce nausea and vomiting and permit more rapid titration of levodopa. nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with carbidopa and levodopa tablets. these inhibitors must be discontinued at least two weeks prior to initiating therapy with carbidopa and levodopa tablets. carbidopa and levodopa tablets